Rabi Hanna MD

Pediatric Hematology & Oncology•Cleveland, OH

Chairman, Pediatric Hematology-Oncology and Blood & Marrow Transplant department Cleveland Clinic Children's

Join to View Full Profile

9500 Euclid AveS-20Cleveland, OH 44195
Phone+1 216-444-0663

Summary

Dr. Rabi Hanna is the chairman of pediatric hematology-oncology department and the medical director of pediatric BMT program at Cleveland Clinic Children's. He received his medical degree from University of Aleppo Faculty of Medicine in 2001. He speaks multiple languages, including Arabic and Assyrian. He is experienced in aplastic anemia, bone marrow transplantation, pediatric hematology and oncology, sickle cell disease, and stem cell transplantation. His research focus on alternative donor and novel therapies for non-malignant disorders including Gene therapies.

Dr. Rabi Hanna - Bio Video

Dr. Rabi Hanna - Cleveland Clinic Children's - Pediatric Hematology and Oncology Physician.

Rabi Hanna, MD | Cleveland Clinic

Find professional and biographical information about Cleveland Clinic physician Rabi Hanna, MD

Education & Training

University of WashingtonFellowship, Pediatric Hematology/Oncology, 2007 - 2010
Duke University HospitalResidency, Pediatrics, 2004 - 2007
University of Aleppo Faculty of MedicineClass of 2001

Certifications & Licensure

OH State Medical License 2010 - 2026
MI State Medical License 2017 - 2021
NY State Medical License 2017 - 2019
WA State Medical License 2007 - 2011
NC State Medical License 2004 - 2007
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

Corkery Fellowship Award Seattle / FHCRC, 2009
James A. Stockman III Award Duke University, 2007
Deborah Kredich Award 2006
Flying Pig award Duke University, 2006
BASSEL award for distinguished study 1996, 2000-2001
Surpassing Award 1992, 1995
Pioneer Student Award in Biology 1989
Join now to see all

Clinical Trials

Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders Start of enrollment: 2006 Jun 01
Completed
Phase 2
MRD Testing Before and After Hematopoietic Cell Transplantation for Pediatric Acute Myeloid Leukemia Start of enrollment: 2011 Oct 01
Completed
Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention Start of enrollment: 2014 Jul 07
Completed
Phase 3
Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204) Start of enrollment: 2013 Dec 01
Completed
Phase 2
Long Term Follow Up Protocol for NiCord®/CordIn™ (Omidubicel) Patients Start of enrollment: 2014 May 01
COMPLETED
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies Start of enrollment: 2015 Mar 01
Active, not recruiting
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma Start of enrollment: 2016 Jun 01
ACTIVE_NOT_RECRUITING
PHASE3
Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS Start of enrollment: 2016 Dec 16
COMPLETED
PHASE3
Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia
COMPLETED
NA
RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome Start of enrollment: 2017 Jun 12
COMPLETED
PHASE1, PHASE2
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Start of enrollment: 2017 Aug 08
ACTIVE_NOT_RECRUITING
PHASE3
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors Start of enrollment: 2017 May 25
RECRUITING
PHASE3
Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507) Start of enrollment: 2017 Oct 03
COMPLETED
PHASE2
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma Start of enrollment: 2019 Jul 08
ACTIVE_NOT_RECRUITING
PHASE2
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) Start of enrollment: 2020 Dec 17
RECRUITING
PHASE2
A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY) Start of enrollment: 2021 May 04
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant Start of enrollment: 2019 Aug 29
RECRUITING
PHASE2
Roles: Contact
Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy Start of enrollment: 2018 Oct 11
TERMINATED
PHASE2
Roles: Principal Investigator
Conditioning SCID Infants Diagnosed Early Start of enrollment: 2018 Oct 22
RECRUITING
PHASE2
Roles: Principal Investigator, Contact
A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II) Start of enrollment: 2023 Feb 28
RECRUITING
PHASE4
Roles: Principal Investigator
Post-trial Access Program of Idursulfase-IT Along With Elaprase in Children With Hunter Syndrome
AVAILABLE
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Dose to circulating blood in intensity-modulated total body irradiation, total marrow irradiation, and total marrow and lymphoid irradiation.
Bingqi Guo, Sheen Cherian, Erin S Murphy, Craig S Sauter, Ronald M Sobecks
Medical Physics. 2025-06-08
Eltrombopag in combination with immunosuppressive therapy in pediatric severe aplastic anemia: Phase 2 ESCALATE trial.
Akiko Shimamura, Alexey Maschan, Caroyln Bennett, Sujith Samarasinghe, Jason E Farrar
Blood Advances. 2025-05-02
Emapalumab treatment in rheumatologic disease-associated hemophagocytic lymphohistiocytosis: a plain language summary.
Shanmuganathan Chandrakasan, Carl E Allen, Deepika Bhatla, John Carter, May Chien
Immunotherapy. 2025-05-01

Journal Articles

Effect of Bone Marrow CD34+Cells and T-cell Subsets on Clinical Outcomes After Myeloablative Allogeneic Hematopoietic Cell Transplantation
Deepa Jagadeesh, Matt Kalaycio, Brian Bolwell, Betty K Hamilton, Brian Hill, Brad Pohlman, Robert Dean, Navneet S Majhail, Sagar S Patel, Rabi Hanna, Aaron T Gerds, Ro..., Nature
Germline Loss of Function SAMD9 and SAMD9L Alterations in Adult Myelodysplastic Syndromes
Samuel Li, Mikkael A Sekeres, Jaroslaw P Maciejewski, Rabi Hanna, Blood
Reduced Intensity Conditioning for Hematopoietic Cell Transplant for HLH and Primary Immune Deficiencies: BMT CTN 1204
Shalini Shenoy, K Scott Baker, Elizabeth O Stenger, Mary Eapen, Carl Allen, Lauri Burroughs, Philip Roehrs, Catherine M Bollard, Rabi Hanna, Jeffrey R Andolina, James ..., Blood
Can we predict hemorrhagic cystitis based on BK viremia?
Rabi Hanna, Biology of Blood and Marrow Transplantation, 8/1/2013
Fractures in children with Pompe disease: a potential long-term complication
Hanna R, Case LE, Frush DP, Krishnamurthy V, Mackey J, Boney A, Chen YT, Kishnani PS, Pediatric Radiology, 5/1/2007
Prevention of Cerebral Ischemia
Hanna R, F. Tanbe, Medical Annals of Aleppo University, 7/1/2001
Diagnostic and treatment challenges of neuropathic Gaucher disease: Two cases with an intermediate phenotype
Hanna R, M. T. McDonald, J. A. Sullivan, J. F. Mackey, V. Krishnamurthy and P. S. Kishnani, J. Inherit. Metab Dis
Join now to see all

Abstracts/Posters

No Engraftment Advantage after Single or Double Umbilical Cord Blood Transplant (CBT) with the Addition of a Non-HLA Matched Off-the-Shelf Expanded Cord Blood Unit Com...
Rabi Hanna, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Interactions between Donor Activating Killer Immunoglobulin-like Receptors (KIRs) and Somatic Mutations and Their Association with Outcomes after Allogeneic Hematopoie...
Rabi Hanna, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Risk factors for infections in recipients of hematopoietic cell transplantation in relation to donor source
Aron Flagg, Rabi Hanna, Lisa A. Rybicki, Sherif B. Mossad, Betty Ky Hamilton, Aaron T. Gerds, Ronald Sobecks, Hien Duong, Steven Andresen, Brian Bolwell, Navneet S Maj..., ASBMT, 1/1/2014
HLA-Mismatch Is Associated With Worse Outcomes after Myeloablative Conditioning and Unrelated Donor Hematopoietic Cell Transplantation: A CIBMTR Analysis
Joseph Pidala MD, MS; Stephanie J. Lee, MD, MPH; Stephen Spellman, MBS; Hai-Lin Wang, MPH; Kwang Woo Ahn, PhD; Mahmoud Aljurf, MD, MPH; Medhat Askar, MD, MPH; Jason De..., ASBMT, 1/1/2014
Long-Term Outcome Of Adolescents and Young Adults (AYA) After Autologous Transplantation For Lymphoma; Single Center Experience With Bu-CY-VP16 Conditioning Therapy
Rabi Hanna, Brian J. Bolwell, Ronald Sobecks, Brad Pohlman, , Deepa Jagadeesh, Hien K. Duong, Brian T. Hill, Betty K. Hamilton, Lisa Rybicki, Matt Kalaycio, Blood, 1/1/2013
The Impact of The Major Histocompatibility Complex Class I-Related Chain A (MICA) and Human Leukocyte Antigen (HLA) -DP Mismatches On Severe Acute GVHD in Patients Rec...
Ronald Sobecks, Aiwen Zhan, Lisa Rybicki, Dawn Thomas, Paul Kawc, Matt Kalaycio, Steven Andresen, Brad Pohlman, Robert Dean, Edward A. Copelan, Rabi Hanna, Hien Duong,..., Blood, 11/16/2012
Risk Factors for the Development of Graft Versus Host Disease in Allogeneic Hematopoietic Stem Cell Tranplantation (allo-HSCT)
Betty K. Hamilton, Lisa Rybicki, Mikkael A. Sekeres, Brian J. Bolwell, Matt Kalaycio, Rabi Hanna, Robert M Dean, Ronald Sobecks, Hien K. Duong, Brian T. Hill, and Edwa..., Blood, 11/16/2012
Racial Differences in Prognostic Factors and Outcomes in Patients Undergoing Allogeneic Hematopoietic Cell Transplant
Betty K. Hamilton, Lisa Rybicki, Mikkael A. Sekeres, Brian J. Bolwell, Matt Kalaycio, Rabi Hanna, Robert M Dean, Ronald Sobecks, Hien K. Duong, Brian T. Hill, and Edwa..., Blood, 11/16/2012
Omission of Methotrexate Doses Due to Toxicity Does Not Influence the Incidence of Gvhd, Relapse, or Survival
Betty K. Hamilton, Housam Haddad, Edward A. Copelan, Lisa Rybicki, Shawnda Tench, Melissa Yurch, Brian J. Bolwell, Rabi Hanna, Ronald Sobecks, Robert M Dean, Hien K. D..., Blood, 11/16/2012
Long-Term Follow-up of a Randomized Trial Comparing Cyclosporine and Short Course Methotrexate with Cyclosporine and Mycophenolate Mofetil for Graft Versus Host Diseas...
Betty K. Hamilton, Housam Haddad, Matt Kaylacio, Lisa Rybicki, Shawnda Tench, Melissa Yurch, Brian J. Bolwell, Rabi Hanna, Ronald Sobecks, Robert M Dean, Hien K. Duong..., Blood, 11/16/2012
Mycophenolate Mofetil Is a Suitable Substitute for Methotrexate for Graft Versus Host Disease Prevention in Myeloablative Allogeneic Hematopoietic Cell Transplantation...
Betty K. Hamilton, Lisa Rybicki, Shawnda Tench, Housam Haddad, Brian J. Bolwell, Rabi Hanna, Ronald Sobecks, Robert M Dean, Hien K. Duong, Brian T. Hill, Edward A. Cop..., Blood, 11/16/2012
Predictions in The Face of Clinical Reality: T-Cell Epitope Classification of HLA-DPB1 Mismatches Does Not Predict Severe Acute GvHD
Medhat Askar, MD, PhD, Jesse Schold, PhD, Jaroslaw Maciejewski, MD, PhD, Robert Dean, MD, Hien Duong, MD, Rabi Hanna, MD, Matt Kalaycio, MD, Edward Copelan, MD, Brian ..., 15th Congress of the European Society for Organ Transplantation, Glasgow, Scotland, 9/4/2011
Acute GVHD in AML and MDS Patients Receiving Matched Related Donor (MRD) Reduced-Intensity Conditioning Allogeneic Hematopoietic Progenitor Cell Transplant (RIC-AHPCT)...
Ronald Sobecks, Aiwen Zhang, Lisa Rybicki, Dawn Thomas, Paul Kawczak, Matt Kalaycio, Steve Andresen, Brad Pohlman, Robert Dean, Edward Copelan, Rabi Hanna, Hien Duong,..., ASH Meeting, San Diego, 1/1/2011
Early Readmission Rates after Autologous and Allogeneic Hematopoietic Progenitor Cell Transplantation (HPCT)
Betty Hamilton, Sheila Serafino, Matt Kalaycio, Steve Andresen, Brad Pohlman, Robert Dean, Brian Hill, Rabi Hanna, Hien Duong, John Sweetenham, Edward Copelan, Brian B..., Cleveland Clinic. ASH meeting, San Diego, 1/1/2011
Osteopenia in Infantile Pompe Disease: An Unrecognized Long Term Complication
Rabi Hanna, Laura E. Case, Vidya Krishnamurthy, Pryia Kishnani, Annual Pediatrics Society Meeting in North Carolina (NCPS), Asheville, NC, 1/1/2005
Two siblings with Gaucher disease who also have Sarcoidisis
Rabi Hanna, Vidya Krishnamurthy, Pryia Kishnani, SIMD (Society for Inherited Metabolic disorders), Phoenix, 1/1/2005
Join now to see all

Lectures

Association of MHC Class I Chain-Related Gene a (MICA) Polymorphisms with Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Pediatric grand round lecture
3/1/2012

Press Mentions

New Gene Therapy at Cleveland Clinic Aims to End Transfusions for ThalassemiaJune 23rd, 2025
Cleveland Clinic Children’s Among First Hospitals to Use Novel Gene Therapy to Treat Inherited Blood DisordersMay 20th, 2025
Rethinking Pediatric Hodgkin Lymphoma CareApril 17th, 2025
Join now to see all